Evaluation of HRPT2 gene abnormalities seems to be a more promising diagnostic tool.(77) Loss of heterozygosity (LOH) or mutation at the HRPT2 gene and loss (total or focal) of parafibromin staining have been reported in the large majority of parathyroid carcinomas but very rarely in adenomas(45,78–81) (Fig. 2). The gene discussed is CDC73; the disease is parathyroid gland carcinoma.